IFN-γ Cancer Research Results

IFN-γ, Interferon-γ: Click to Expand ⟱
Source:
Type:
Plays a key role in activation of cellular immunity and subsequently, stimulation of antitumor immune-response. Based on its cytostatic, pro-apoptotic and antiproliferative functions, IFN-γ is considered potentially useful for adjuvant immunotherapy for different types of cancer.
Moreover, it IFN-γ may inhibit angiogenesis in tumor tissue, induce regulatory T-cell apoptosis, and/or stimulate the activity of M1 proinflammatory macrophages to overcome tumor progression.
However, the current understanding of the roles of IFN-γ in the tumor microenvironment (TME) may be misleading in terms of its clinical application.

IFN-γ is often expressed in the tumor microenvironment, particularly in response to immune cell infiltration. Its expression can be influenced by the presence of tumor-infiltrating lymphocytes (TILs) and other immune cells.
High levels of IFN-γ are typically associated with a Th1 immune response, which is generally considered beneficial for anti-tumor immunity.

Tumor Suppression:
In many cases, IFN-γ has tumor-suppressive effects, as it can inhibit tumor cell proliferation and induce apoptosis in certain cancer types.


BC, Breast Cancer: Click to Expand ⟱
Breast Cancer

Scientific Papers found: Click to Expand⟱
1000- AG,  5-FU,    Characterization and anti-tumor bioactivity of astragalus polysaccharides by immunomodulation
- vitro+vivo, BC, 4T1
TumCG↓, TumCCA↑, Apoptosis↑, *IL2↑, *TNF-α↑, *IFN-γ↑,
6749- DHA,    The effects of docosahexaenoic acid (DHA) on plasma cytokines, oxylipins, and tumor-infiltrating lymphocytes from women with breast cancer undergoing neoadjuvant chemotherapy in the DHA-WIN trial
- Trial, BC, NA
*IFN-γ↑, *TNF-α↑, Imm↑,
6750- DHA,  Chemo,    Docosahexaenoic acid (DHA) supplementation attenuates changes in the concentration, phenotype, and response of immune peripheral blood cells in breast cancer patients undergoing neoadjuvant therapy. Secondary findings from the DHA-WIN trial
- Trial, BC, NA
*CD14↑, *NLR↓, eff↑, *IL4↑, *IL10↑, *IFN-γ↑, *TNF-α↑, Imm↑, eff↑, TumW↓,
5602- NaHCO3,  immuno,    Immunotherapy Enhancement by Targeting Extracellular Tumor pH in Triple-Negative Breast Cancer Mouse Model
- in-vivo, BC, 4T1
eff↑, TumCG↓, OS↑, e-pH↑, IFN-γ↑, IL2↑, IL12↑, Dose↝, PD-L1↓,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death(tgid=5)

Apoptosis↑, 1,  

Cell Cycle & Senescence(tgid=11)

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12)

TumCG↓, 2,  

Immune & Inflammatory Signaling(tgid=16)

IFN-γ↑, 1,   IL12↑, 1,   IL2↑, 1,   Imm↑, 2,   PD-L1↓, 1,  

Cellular Microenvironment(tgid=17)

e-pH↑, 1,  

Drug Metabolism & Resistance(tgid=21)

Dose↝, 1,   eff↑, 3,  

Clinical Biomarkers(tgid=22)

PD-L1↓, 1,  

Functional Outcomes(tgid=23)

OS↑, 1,   TumW↓, 1,  
Total Targets: 14

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0)

NLR↓, 1,  

Immune & Inflammatory Signaling(tgid=16)

CD14↑, 1,   IFN-γ↑, 3,   IL10↑, 1,   IL2↑, 1,   IL4↑, 1,   TNF-α↑, 3,  
Total Targets: 7

Scientific Paper Hit Count for: IFN-γ, Interferon-γ
2 Docosahexaenoic Acid
1 Astragalus
1 5-fluorouracil
1 Chemotherapy
1 Bicarbonate(Sodium)
1 immunotherapy
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:4  Cells:%  prod#:%  Target#:442  State#:%  Dir#:2
wNotes=0 sortOrder:rid,rpid

 

Home Page